Login / Signup

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.

Adeniyi OlagunjuAdeola FowotadeAjibola OlagunoyeTemitope Olumuyiwa OjoBolanle Olufunlola AdefuyeAdeniyi Francis FagbamigbeAkindele Olupelumi AdebiyiOmobolanle Ibitayo OlagunjuOlabode Taiwo LadipoAbdulafeez AkinloyeBabatunde Ayodeji AdeagboAdedeji OnayadeOluseye Oladotun BolajiChristian HappiSteve RannardAndrew Owen
Published in: Trials (2021)
The full protocol is attached as an additional file which will be made available on the trial website. In the interest of expediting dissemination of this material, the traditional formatting has been eliminated, and this letter serves as a summary of the key elements in the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
Keyphrases
  • randomized controlled trial
  • study protocol
  • coronavirus disease
  • clinical trial
  • sars cov
  • clinical practice
  • early onset
  • phase iii
  • open label
  • antiretroviral therapy
  • double blind
  • replacement therapy